DLGAP4 Knockout A2780 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population originating from the A2780 human epithelial ovarian cancer cell line, with targeted disruption of the DLGAP4 gene. This heterogeneous pool contains diverse edited alleles, enabling robust assessment of DLGAP4 loss-of-function effects without the need for clonal isolation. The model is optimized for in vitro functional studies and is supplied as a ready-to-use polyclonal knockout cell product.
The A2780 host cell line is a cisplatin-sensitive, hormone-responsive epithelial ovarian carcinoma line derived from an untreated patient, serving as a standard model for ovarian cancer research. Its consistent growth characteristics and well-documented genetic profile facilitate investigations into tumor biology, drug sensitivity, and mechanisms of platinum-based chemoresistance. A2780 cells retain key primary tumor traits, including epithelial morphology and hormone responsiveness, making them particularly valuable for translational studies.
DLGAP4 is a postsynaptic scaffold protein that links neurotransmitter receptors to the cytoskeleton at glutamatergic synapses. It forms a core complex with PSD-95 (DLG4) and SHANK proteins, and its activity is regulated upstream by NMDA receptor activation, CaMKII phosphorylation, and CREB-mediated transcription. Downstream, DLGAP4-dependent scaffolds promote surface retention of AMPA receptors and F-actin polymerization through interactions with HOMER proteins and the actin cytoskeleton. Thus, the established pathway proceeds from NMDA receptor ?? PSD-95 ?? DLGAP4 ?? SHANK/HOMER ?? AMPA receptor/F-actin, coupling synaptic activity to structural plasticity. Outside the nervous system, analogous protein modules may similarly govern cell adhesion and cytoskeletal organization.
In epithelial ovarian cancer, the DLGAP4 interactome may be co-opted to regulate cell?Cextracellular matrix adhesion, actin dynamics, and invasive capacity, presenting a compelling context for this knockout model. Disruption of DLGAP4 in the cisplatin-sensitive A2780 background allows systematic analysis of how loss of this scaffold influences proliferation, migration, invasion, and response to platinum-based chemotherapy. By perturbing DLGAP4-mediated junctional and cytoskeletal organization, these cells offer a valuable tool for probing the molecular basis of chemoresistance and metastatic behavior in ovarian carcinoma.
This polyclonal knockout model is suited for diverse applications, including ovarian cancer cell biology, chemoresistance mechanism dissection, and protein?Cprotein interaction studies. Compatible assays range from western blotting and RT-qPCR for expression analysis, to MTT and Transwell-based assays for proliferation, migration, and invasion, as well as cisplatin sensitivity profiling. Co-immunoprecipitation and immunofluorescence microscopy enable detailed characterization of DLGAP4-containing complexes and their localization. For technical inquiries, custom configurations, or ordering, please contact Ascent Research.
